Thynk Health, LLC

Thynk Health, based in the US, provides innovative AI-driven solutions focused on improving patient management across various health pathways, including cancer screening and diagnostic follow-ups. Thynk Health, established in 2014 in Lexington, US, specializes in healthcare technology solutions. The company has successfully completed one funding deal, with their most recent deal occurring on April 28, 2026. The company does not have any known subsidiaries and has not undergone significant pivots since its inception.

Thynk Health specializes in comprehensive AI-driven solutions targeted at various health pathways, including pulmonary, cardiovascular, digestive, liver, endocrine, GU, women's health, and emergency care. Their core offerings focus on unifying early detection, longitudinal tracking, and diagnostic follow-up to address actionable findings across multiple organ systems. The technology incorporates advanced AI capabilities such as Natural Language Processing (NLP) and Large Language Models (LLMs) to reveal hidden clinical insights and facilitate proactive patient management. Thynk Health primarily serves healthcare providers, including hospitals and clinics, enhancing patient journeys by automating follow-ups and improving treatment outcomes through insightful analytics.

The company's products are deployed primarily in the United States, addressing a significant need for innovative healthcare solutions in a rapidly evolving market. Thynk Health operates on a business-to-business model, engaging healthcare providers through subscriptions and partnerships that facilitate access to their patient management software suite. This model allows clients to integrate Thynk Health's solutions into their existing systems, ultimately enhancing their capabilities in managing incidental findings and cancer screening programs. While specific pricing plans for their flagship products and services are not disclosed, the revenue structure includes tiered subscription fees correlated with the scale of service utilized by each healthcare provider.

This transactional framework supports Thynk Health's mission to deliver actionable healthcare insights and improve patient outcomes, ensuring that critical findings are managed effectively and efficiently across their client base. In April 2026, Azra AI, a portfolio company of SJF Ventures, acquired Thynk Health, LLC. This acquisition enables Azra AI to add lung cancer screening and incidental findings management to its platform, extending coverage from detection to treatment. The combined solution aims to reduce gaps between imaging and care, improving continuity from diagnosis through treatment.